Talking viruses, pan-coronavirus antivirals, and the importance of in silico design

What was it like to keep research work going during the worst of the pandemic? And how close are we to a vaccine that works against all current and future coronavirus variants? We will discuss that plus biochemistry, biosystems, and in silico design in this episode with Dr. Imre Berger. Dr. Berger is a professor of Biochemistry at the University of Bristol; Director for the Max Planck Bristol Centre for Minimal Biology; and co-founder and chief strategy officer at Halo Therapeutics, a University of Bristol spin-out. He has been published in countless scientific and academic journals, and his work covers multiple areas of biochemistry. His recent work has been focused on coronaviruses, specifically developing pan-coronavirus antivirals at Halo Therapeutics. Learn more at www.halo-therapeutics.com Learn more about how Oracle for Research can help you speed up your research with grants, cloud computing, and hands-on support and expertise. www.oracle.com/research